Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Bones, heart and the new anabolic agent romosozumab.

Pazianas M.

Postgrad Med J. 2019 Aug 17. pii: postgradmedj-2019-136699. doi: 10.1136/postgradmedj-2019-136699. [Epub ahead of print] No abstract available.

PMID:
31422376
2.

Letter to the Editor: "Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women".

Pazianas M.

J Clin Endocrinol Metab. 2019 Sep 1;104(9):3609. doi: 10.1210/jc.2019-00785. No abstract available.

PMID:
30990528
3.

FGF-23 in untreated nephrotic syndrome and effects of the renin-angiotensin-aldosterone system.

Pazianas M.

Nephrology (Carlton). 2019 Feb;24(2):273. doi: 10.1111/nep.13266. No abstract available.

PMID:
30697887
4.

Does bisphosphonate treatment reduce the risk of future cancer?

Pazianas M, Abrahamsen B.

Chin Clin Oncol. 2018 Oct 27. pii: cco.2018.10.08. doi: 10.21037/cco.2018.10.08. [Epub ahead of print] No abstract available.

5.

Effectiveness of calcium and vitamin D supplementation in osteoporosis.

Pazianas M.

Ann N Y Acad Sci. 2018 Dec;1433(1):5-6. doi: 10.1111/nyas.13658. Epub 2018 Mar 25. No abstract available.

PMID:
29574761
6.

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study.

Garriga C, Pazianas M, Hawley S, Delmestri A, Prieto-Alhambra D, Cooper C, Judge A.

Ann N Y Acad Sci. 2018 Mar;1415(1):34-46. doi: 10.1111/nyas.13589. Epub 2018 Jan 24.

7.

Beyond ONJ - A review of the potential uses of bisphosphonates in dentistry.

Shah NP, Nayee S, Pazianas M, Sproat C.

Br Dent J. 2017 May 12;222(9):727-730. doi: 10.1038/sj.bdj.2017.412. Review.

PMID:
28496240
8.

Oestrogens and ageing from the skeletal perspective.

Pazianas M.

Postgrad Med J. 2017 Mar;93(1097):113-114. doi: 10.1136/postgradmedj-2016-134664. Epub 2017 Jan 4. No abstract available.

PMID:
28053223
9.

Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?

Pazianas M, Abrahamsen B.

Ann N Y Acad Sci. 2016 Jul;1376(1):5-13. doi: 10.1111/nyas.13166. Epub 2016 Aug 15.

PMID:
27525578
10.

Periodontal Disease, Dental Implants, Extractions and Medications Related to Osteonecrosis of the Jaws.

Shah NP, Katsarelis H, Pazianas M, Dhariwal DK.

Dent Update. 2015 Nov;42(9):878-80, 883-4, 887-89. Review.

PMID:
26749795
11.

Infection and medication-related osteonecrosis of the jaw.

Katsarelis H, Shah NP, Dhariwal DK, Pazianas M.

J Dent Res. 2015 Apr;94(4):534-9. doi: 10.1177/0022034515572021. Epub 2015 Feb 20. Review.

PMID:
25710950
12.

Calcium supplements controversy in osteoporosis: a physiological mechanism supporting cardiovascular adverse effects.

Paziana K, Pazianas M.

Endocrine. 2015 Apr;48(3):776-8. doi: 10.1007/s12020-015-0550-9. Epub 2015 Feb 17.

PMID:
25687221
13.

Anabolic effects of PTH and the 'anabolic window'.

Pazianas M.

Trends Endocrinol Metab. 2015 Mar;26(3):111-3. doi: 10.1016/j.tem.2015.01.004. Epub 2015 Feb 5.

PMID:
25662368
14.

Questioning the association between bisphosphonates and atypical femoral fractures.

Pazianas M, Kim SM, Yuen T, Sun L, Epstein S, Zaidi M.

Ann N Y Acad Sci. 2015 Jan;1335:1-9. doi: 10.1111/nyas.12551. Epub 2014 Oct 7. Review.

15.

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.

Pazianas M, Abrahamsen B.

Osteoporos Int. 2014 Nov;25(11):2669. doi: 10.1007/s00198-014-2788-0. Epub 2014 Jul 18. No abstract available.

PMID:
25035137
16.

Bisphosphonates and bone quality.

Pazianas M, van der Geest S, Miller P.

Bonekey Rep. 2014 May 7;3:529. doi: 10.1038/bonekey.2014.24. eCollection 2014. Review.

17.

Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts.

Pazianas M, Smith R.

J Clin Endocrinol Metab. 2014 Jul;99(7):2340-2. doi: 10.1210/jc.2014-1375. Epub 2014 Apr 8. No abstract available.

PMID:
24712575
18.

Eliminating the need for fasting with oral administration of bisphosphonates.

Pazianas M, Abrahamsen B, Ferrari S, Russell RG.

Ther Clin Risk Manag. 2013;9:395-402. doi: 10.2147/TCRM.S52291. Epub 2013 Oct 18.

19.

Safety issues with bisphosphonate therapy for osteoporosis.

Suresh E, Pazianas M, Abrahamsen B.

Rheumatology (Oxford). 2014 Jan;53(1):19-31. doi: 10.1093/rheumatology/ket236. Epub 2013 Jul 9. Review.

PMID:
23838024
20.

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.

Abrahamsen B, Pazianas M, Russell RG.

BMJ. 2013 Mar 12;346:f1514. doi: 10.1136/bmj.f1514. No abstract available.

PMID:
23482976
21.

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?

Pazianas M.

JAMA Intern Med. 2013 Jan 14;173(1):79-80. doi: 10.1001/2013.jamainternmed.753. No abstract available.

PMID:
23318593
22.

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.

Pazianas M, Clark EM, Eiken PA, Brixen K, Abrahamsen B.

J Bone Miner Res. 2013 Mar;28(3):455-63. doi: 10.1002/jbmr.1783.

23.

Bisphosphonates and colon cancer: reply.

Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG.

Osteoporos Int. 2013 Mar;24(3):1141-2. doi: 10.1007/s00198-012-2079-6. Epub 2012 Jul 31. No abstract available.

PMID:
22847317
24.

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Pazianas M, Abrahamsen B, Wang Y, Russell RG.

Osteoporos Int. 2012 Dec;23(12):2873-84. doi: 10.1007/s00198-012-1952-7. Epub 2012 Mar 20.

PMID:
22431012
25.

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.

Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG.

Osteoporos Int. 2012 Nov;23(11):2693-701. doi: 10.1007/s00198-012-1902-4. Epub 2012 Mar 6.

PMID:
22392160
26.

Potential therapeutic effects of oral bisphosphonates on the intestine.

Pazianas M, Russell RG.

Ann N Y Acad Sci. 2011 Dec;1240:E19-25. doi: 10.1111/j.1749-6632.2011.06372.x. Review.

PMID:
22360293
27.

Esophageal and gastric cancer incidence and mortality in alendronate users.

Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R.

J Bone Miner Res. 2012 Mar;27(3):679-86. doi: 10.1002/jbmr.1481.

28.

Atrial fibrillation and the use of oral bisphosphonates.

Pazianas M, Cooper C, Wang Y, Lange JL, Russell RG.

Ther Clin Risk Manag. 2011;7:131-44. doi: 10.2147/TCRM.S17899. Epub 2011 Mar 22.

29.

Safety of bisphosphonates.

Pazianas M, Abrahamsen B.

Bone. 2011 Jul;49(1):103-10. doi: 10.1016/j.bone.2011.01.003. Epub 2011 Jan 12. Review.

PMID:
21236370
30.

Osteonecrosis of the jaw and the role of macrophages.

Pazianas M.

J Natl Cancer Inst. 2011 Feb 2;103(3):232-40. doi: 10.1093/jnci/djq516. Epub 2010 Dec 28. Review.

PMID:
21189409
31.

High-dose oral vitamin D supplementation and risk of falls in older women.

Prieto-Alhambra D, Judge A, Pazianas M.

JAMA. 2010 Aug 25;304(8):854-5; author reply 856-7. doi: 10.1001/jama.2010.1166. No abstract available.

PMID:
20736463
32.

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.

Pazianas M, Cooper C, Ebetino FH, Russell RG.

Ther Clin Risk Manag. 2010 Jul 21;6:325-43.

33.

Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders: comment on the article by Kling et al.

Pazianas M.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):902. doi: 10.1002/acr.20134. No abstract available.

34.

Macrophages in Hodgkin's lymphoma.

Pazianas M.

N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136. No abstract available.

PMID:
20527079
35.

Atrial fibrillation and bisphosphonate therapy.

Pazianas M, Compston J, Huang CL.

J Bone Miner Res. 2010 Jan;25(1):2-10. doi: 10.1359/jbmr.091201. Review.

36.

Evaluating the antifracture efficacy of bisphosphonates.

Pazianas M, Epstein S, Zaidi M.

Rev Recent Clin Trials. 2009 May;4(2):122-30. Review.

PMID:
19463108
37.

Calcific aortic stenosis.

Pazianas M.

N Engl J Med. 2009 Jan 1;360(1):85; author reply 85-6. doi: 10.1056/NEJMc082192. No abstract available.

PMID:
19118311
38.

Osteonecrosis of the jaw: more heat than light.

Pazianas M, Russell RG, Fogelman I.

J Nucl Med. 2009 Jan;50(1):6-7. doi: 10.2967/jnumed.108.057885. Epub 2008 Dec 17. No abstract available.

39.
40.
41.

Systemic inflammatory mediators and bone homeostasis in intestinal failure.

Compher C, Pazianas M, Benedict S, Brown JC, Kinosian BP, Hise M.

JPEN J Parenter Enteral Nutr. 2007 Mar-Apr;31(2):142-7.

PMID:
17308255
42.

Intestinal failure-associated metabolic bone diseases and response to teriparatide.

Pazianas M, Compher C, Schiavone-Gatto P, Kinosian BP.

Nutr Clin Pract. 2006 Dec;21(6):605-9.

PMID:
17119166
43.

Prevention and treatment of osteoporosis in inflammatory bowel disease.

Lichtenstein GR, Sands BE, Pazianas M.

Inflamm Bowel Dis. 2006 Aug;12(8):797-813. Review.

PMID:
16917235
44.

The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.

Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR.

Ann N Y Acad Sci. 2006 Apr;1068:543-56.

PMID:
16831950
45.

Acute renal failure and hypercalcaemia in a man from Guyana: what is the link?

Wang JH, Pazianas M, Fraser WD, Harris F, Eastwood JB.

Nephrol Dial Transplant. 2005 Jul;20(7):1505-8. Epub 2005 May 10. No abstract available.

PMID:
15886219
46.

Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis.

Campbell MS, Lichtenstein GR, Rhim AD, Pazianas M, Faust T.

Liver Int. 2005 Apr;25(2):311-6.

PMID:
15780055
47.

Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake.

Pazianas M, Butcher GP, Subhani JM, Finch PJ, Ang L, Collins C, Heaney RP, Zaidi M, Maxwell JD.

Osteoporos Int. 2005 Jan;16(1):56-63. Epub 2004 Jun 17.

PMID:
15221205
48.

Efferent loop small intestinal vitamin D receptor concentration and bone mineral density after Billroth II (Polya) gastrectomy in humans.

Pazianas M, Zaidi M, Subhani JM, Finch PJ, Ang L, Maxwell JD.

Calcif Tissue Int. 2003 Apr;72(4):485-90. Epub 2003 Feb 10.

PMID:
12574872
49.

Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.

Verma A, Maxwell JD, Ang L, Davis T, Hodges S, Northfield TC, Zaidi M, Pazianas M.

Osteoporos Int. 2002 Aug;13(8):677-82.

PMID:
12181628
50.

Two underlying diseases causing hypercalcaemia?

Pazianas M, Zaidi M.

Nephrol Dial Transplant. 2002 Jun;17(6):1141; author reply 1141. No abstract available.

PMID:
12032215

Supplemental Content

Loading ...
Support Center